PubMed Health⌕ Search

Biomedical subjects

A Gill

Publications and source records attributed to A Gill.

79 records · Page 5Linked to original sources
PubMedDate not supplied

Should non-patient volunteers donate eggs?

Egg donation is associated with medical and surgical risks regardless of the source of eggs, be it through commercial, altruistic or more recent egg-share donors. Egg sharing is the only system that does not turn a healthy woman (the donor) into a patient. Using carefully selected egg-share donors, pregnancy rates for both donor and recipient are as good as any egg-donation programme, with one cohort of eggs being used with more efficiency. We propose that anonymous egg sharing, as licensed by the Human Fertilisation and Embryology Authority (HFEA), minimizes risk, is ethically sound and should be considered as the only acceptable form of anonymous egg donation.

Altruism↗
PubMedDate not supplied

Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs.

The recommended treatment for canine ehrlichiosis is tetracycline or its analog doxycycline, although recent reports have documented ineffective clearing of Erchlichia canis after doxycycline administration. Imidocarb dipropionate is used as an alternative treatment to tetracycline or is used in conjunction with doxycycline. The effectiveness of imidocarb dipropionate in clearing Ehrlichia species from the blood and tissues of dogs with E. canis infection has not been thoroughly evaluated. Fifteen dogs were experimentally infected with E. canis. Ten dogs were treated with imidocarb dipropionate (6.6 mg/kg, IM, 2 injections given 2 weeks apart). Five infected control dogs were not treated. Blood samples from all 15 dogs were E. canis DNA positive by PCR assay by 3 weeks after inoculation (PI), and E. canis antibodies were detected by IFA assay by 1 week PI. Blood platelet counts in all dogs were below the reference interval by 4 weeks PI. E. canis DNA was detected in bone marrow and splenic aspirates by PCR assay 4 weeks PI but not before infection. Bone marrow aspirates were E. canis DNA positive by PCR assay in 14/15 dogs, and splenic aspirates were E. canis DNA positive by PCR assay in 13/15 dogs. Blood samples from all treated and control dogs remained positive for E. canis DNA by PCR assay, and platelet counts remained below preinoculation values 13 weeks PI (6 weeks after 2nd treatment). As administered in this study, imidocarb dipropionate did not clear experimental E. canis infection in dogs.

Animals↗
PubMedDate not supplied

[Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].

In this study, the relationship between gyrA mutations and ciprofloxacin minimum inhibitory concentration (MIC) values was investigated in Escherichia coli strains. For this purpose, ciprofloxacin MIC values of 46 E. coli strains, isolated from out-patients and hospitalized patients, were determined by the agar dilution method. The "Quinolone Resistance Determining Region" (QRDR) of gyrA gene was amplified and restricted by Hinf-I enzyme. Ser-83 mutation was observed in all strains that have ciprofloxacin MIC values of 0.062 mg/L and higher. Afterwards, eight strains, that were found susceptible (MIC < 1 mg/L, n: 1), intermediate (MIC: 1-4 mg/L, n: 1) and high level resistant (MIC > 4 mg/L, n: 6) to ciprofloxacin, were chosen and mutations in QRDRs of these strains investigated by DNA sequence analysis. Ser 83 Leu mutation was found in all the chosen strains and Asp 87 Tyr or Asp 87 Asn mutations were also observed except the ciprofloxacin susceptible (MIC: 0.062 mg/L) one. In addition, base substitutions that don't lead to aminoacid changes were detected. The strain in which only Ser 83 Leu mutation was observed, showed high level nalidixic acid resistance (MIC > 256 mg/L). This fact was in favour of that, one mutation is enough to develop high level resistance to nalidixic acid. It was concluded that high level ciprofloxacin resistance requires at least two mutations in the QRDR of gyrA gene.

Anti-Infective Agents↗
PubMedDate not supplied

Evaluation of California's statewide implementation of enhanced perinatal services as Medicaid benefits.

The authors evaluated enhanced perinatal services developed by public health specialists that were implemented statewide through specially certified Medicaid providers to find out whether they were as effective as those services originally tested in the public health agency's pilot project, and more effective than services from regular Medicaid providers. Multivariate logistic regression analyses yielded adjusted odds ratios of use of care and health outcome measures for the statewide services compared with both the pilot project and routine Medicaid care. Although women receiving the enhanced services implemented statewide did not return for prenatal visits as well as those in the pilot project, they did better than women with routine Medicaid providers. Women who kept at least the eight prenatal visits recommended by the Public Health Service in 1989 had risks of low weight births no different from those in the pilot project and significantly better than those for women with at least eight visits with routine Medicaid providers (adjusted odds ratio 0.70 with a 95 percent confidence interval from 0.54 to 0.91). Thus, there is evidence for the efficacy of the services, but additional improvement could be realized through improving the use of care.

California↗